European Journal of Cancer
Volume 40, Issue 4 , Pages 521-528 , March 2004

Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP)

  • C. Rodary

      Affiliations

    • Department of Public Health, Institut Gustave Roussy, 39 rue Camille Desmoulin, 94805 Villejuif, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-1-4211-4128; fax: +33-1-1211-5258
    • ,
  • V. Pezet-Langevin

      Affiliations

    • Department of Public Health, Institut Gustave Roussy, 39 rue Camille Desmoulin, 94805 Villejuif, France
    • ,
  • S. Garcia-Acosta

      Affiliations

    • Department of Public Health, Institut Gustave Roussy, 39 rue Camille Desmoulin, 94805 Villejuif, France
    • ,
  • T. Lesimple

      Affiliations

    • Centre Eugène Marquis, 35052 Rennes, France
    • ,
  • A. Lortholary

      Affiliations

    • Centre Paul-Papin, 49036 Angers, France
    • ,
  • M.C. Kaminsky

      Affiliations

    • Centre Alexis-Vautrin, 54511 Vandoeuvre-Les-Nancy, France
    • ,
  • J. Bennouna

      Affiliations

    • Centre René-Gauducheau, 44805 Saint-Herblain, France
    • ,
  • S. Culine

      Affiliations

    • Centre Val-d'Aurelle, 34094 Montpellier, France
    • ,
  • H. Bourgeois

      Affiliations

    • CHU La Milétrie, 86021 Poitiers, France
    • ,
  • Karim Fizazi

      Affiliations

    • Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulin 94805 Villejuif, France

Received 10 February 2003 ,Revised 18 September 2003 ,Accepted 4 November 2003.

References 

  1. Leplège A, Hunt S. The problem of quality of life in medicine. JAMA. 1997;278:47–50
  2. Culine S, Kramar A, Saghatchian , et al.  Development and validation of a prognostic model to predict survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679–4683
  3. Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329:257–263
  4. Aaronson N, Ahmedzai S, Bergman B, et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J. Nat. Cancer Inst. 1993;85:365–376
  5. Cella D, Tulsky DS, Gray D, et al.  The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  6. Varricchio CG, McCabe MS, Trimble E, Korn EL. Quality of Life in clinical cancer trials. J Natl Cancer Inst (monograph). 1996;20:1–113
  7. Cella D, Wester K. Linking outcomes management to quality-of-life measurement. Oncology. 2002;11:232–235
  8. Kemmler G, Holzner B, Kopp M, et al.  Comparison of two quality-of-life instruments for cancer patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932–2940
  9. Conroy T, Mercier M, Schraub S, et al.  Comparison of three quality of life instruments for cancer patients: FACT-G, EORTC QLQ-C30 and FLIC. Quality Life Res. 2000;9:274
  10. World Health Organization. Handbook for Reporting Results of Cancer Treatments. Geneva: WHO; 1979;
  11. Bonomi A, Cella D, Hahn A, et al.  Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality Life Res. 1996;5:309–320
  12. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies. 2nd edn. Oxford, UK: Blackwell Science; 1997;
  13. Bowling A. Research Methods in Health. Buckingham: Open University Press; 2002;
  14. Ware JE, Harris WJ, Gandek B, Rogers BW, Reese PR. MAP-R for Windows: Multitrait/Multi-Item Analysis Program—Revised User's Guide. Boston, MA: Assessment Lab; 1997;
  15. Culine S, Lortholary A, Voigt JJ, et al.  Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of an Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479–3482
  16. Curran D, Fayers PM, Molenberghs G, Machin D. Analysis of incomplete quality of life data in clinical trials. In Staquet MJ, Hays RD, Fayers PM, eds. Quality of Life Assessment in Clinical Trials. Oxford, Oxford University Press, 1998; 256.
  17. Fairclough D, Cella D. Functional Assessment of Cancer Therapy (FACT-G) (non-response to individual questions). Quality Life Res. 1996;5:321–329
  18. Lent L, Hahn E, Eremenco S, Webster K, Cella D. Using cross-cultural input to adapt the Functional Assessment of Chronic Illness Therapy (FACIT). Acta Oncol. 2002;38:695–702

PII: S0959-8049(03)00960-2

doi: 10.1016/j.ejca.2003.11.002

European Journal of Cancer
Volume 40, Issue 4 , Pages 521-528 , March 2004

Article Tools